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Abstract
Optimal conditioning therapy for hematopoietic cell transplantation (HCT) in acute myelogenous leukemia (AML)
remains undefined. We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with
oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100
consecutive AML patients treated with pharmacokinetic targeted IV busulfan (AUC < 6000 μM/L*min per day ×
4 days) and fludarabine (40 mg/m2 × 4 days) - (t-IV Bu/Flu). The Bu/Cy and t-IV Bu/Flu groups significantly differed
according to donor relation, stem cell source, aGVHD prophylaxis, remission status, primary vs. secondary disease,
median age, and % blasts prior to HCT (p < 0.01 for each). Conditioning with t-IV Bu/Flu reduced early toxicity
including idiopathic pneumonia syndrome (IPS) and hepatic veno-occlusive disease (VOD). Additionally, the trajec-
tory of early NRM (100 day: 16% vs. 3%, and1 year: 25% vs. 15% for Bu/Cy and t-IV Bu/Flu, respectively) favored t-IV
Bu/Flu. Grade II-IV aGVHD (48% vs. 82%, p < 0.0001), as well as moderate/severe cGVHD (7% vs. 40%, p < 0.0001)
differed between the Bu/Cy and t-IV Bu/Flu groups, due to the predominance of peripheral blood stem cells in the
t-IV Bu/Flu group. Pharmacokinetic targeting of intravenous busulfan in combination with fludarabine is associated
with reduced conditioning regimen related toxicity compared to oral busulfan and cyclophosphamide. However,
multivariable analysis did not demonstrate significant differences in overall survival (p = 0.78) or non-relapse
mortality (p = 0.6) according to conditioning regimen delivered.
Background
Ongoing investigation aims to preserve efficacy, but
reduce morbidity and mortality associated with condi-
tioning therapy for allogeneic hematopoietic cell trans-
plantation (HCT). Seminal work has demonstrated
variation in bioavailability of oral busulfan (Bu), and the
correlation between busulfan exposure and both toxicity
including hepatic veno-occlusive disease, [1] as well as
graft rejection and primary disease relapse.(8, 9) In the
setting of both oral and intravenous administration of
busulfan, inter-patient variation is observed [2]. Impor-
tantly, the intended busulfan exposure differs according
to individual transplantation conditioning regimens,
such as Bu/Cyclophosphamide(Cy) and Bu/Fludarabine
(Flu). As well, in the context of Cy/total body irradiation
(TBI) based conditioning therapy, McDonald, et al have
demonstrated increased non-relapse mortality and
reduced overall survival associated with exposure to
toxic metabolites of cyclophosphamide [3]. Conversely,
fludarabine given in combination with targeted oral [4]
or intravenous busulfan [5,6] has been demonstrated
safe and effective as conditioning therapy for HCT in
myeloid malignancies.
With the intention of reducing transplant related toxi-
city, as well as expanding access to patients of older age
or more advanced comorbidity, a number of reduced to
intermediate-intensity, or truly non-myeloablative regi-
mens have been developed [4,5,7-15]. Our center adopted
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2004 onward as a uniform conditioning strategy in the
setting of allogeneic transplantation for acute myelogen-
ous leukemia. As the regimen appears to result in
reduced treatment related toxicity compared to our
center’s historical experience with oral busulfan and
cyclophosphamide, we aimed to confirm these observa-
tions in a comparative analysis of outcomes of AML
patients.
Methods
Patients
All consecutive acute myelogenous leukemia (AML)
patients treated with a conditioning regimen of targeted
IV busulfan and fludarabine (t-IV Bu/Flu) at Moffitt
Cancer Center from 2004 to 2008 with a minimum
follow up of one year were identified. These were com-
pared to a consecutive historical cohort of 51 consecutive
AML patients treated with oral Busulfan and Cyclopho-
sphamide (Bu/Cy) at the Center from 1997 to 2004.
T h e s ed a t ad e m o n s t r a t eat r e n db yw h i c ho u rc e n t e r ’s
volume of allogeneic transplants for AML have substan-
tially increased over this time frame. As well, supportive
care practices and program faculty have changed over
this time frame. All patients provided informed consent
for follow up of transplant outcome data. The reporting
of this data was approved by the University of South
Florida Institutional Review Board.
Conditioning, GVHD prophylaxis, and supportive care
The conditioning regimen in the t-IV Bu/Flu group con-
sisted in all cases of Fludarabine, 40 mg/m
2 infused over
30 minutes daily on days -6 to -3, followed by intrave-
nous Busulfan, 130-145 mg/m2 over 4 hours daily on
the same days. Busulfan (BU) pharmacokinetic samples
were obtained on day -6 and analyzed by mass spectro-
metry in the clinical toxicology lab at the University of
Pennsylvania. Analysis utilized a one compartment
model with first order kinetics. On days -4 and -3, the
BU dose was adjusted to target an average AUC of 5300
(+/-10%) μMol*min (n = 96) or 3500 (+/-10%) μMol*-
m i n( n=4 )f o re a c ho ft h ef o u rd a y s .T h el o w e rt a r g e t
AUC of 3500 was chosen in these 4 cases due to patient
age, ranging from 62 to 67. The Bu/Cy regimen con-
sisted in all cases of oral busulfan 1 mg/kg every
6 hours for 4 days (days -7 to -4) for a total of 16 doses,
as well as cyclophosphamide 60 mg/kg IV × 2 days
(days -3 to -2). Pharmacokinetic measurements were not
performed in this group. Stem cell source and GVHD
prophylaxis are reported in table 1.
Outcomes
Neutrophil engraftment was defined by the first of three
successive days with an absolute neutrophil count of
greater than 500/uL. Platelet engraftment was defined by
the first of three successive days with a non-transfused
platelet count of greater than 20,000/uL. The occurrence
and severity of hepatic sinusoidal obstructive syndrome
(veno-occlusive disease) were recorded using the pre-
viously described criteria [16,17]. Acute graft vs. host dis-
ease (aGVHD) was scored per modified Glucksberg
criteria [18]. Chronic graft vs. host disease (cGVHD) was
scored per proposed NIH consensus criteria [19]. Periph-
eral blood sorted (CD3 and CD33) and bone marrow
donor chimerism were assessed by PCR. Primary disease
restaging occurred in all cases at minimum on days 30,
90, 180, and 360, as well as at 18 months, and 2 years.
Statistical analysis
Differences in baseline characteristics were compared
with Wilcoxon rank-sum test for numerical or ordinal
variables, and Chi-square test or Fisher exact test for
categorical variables. Time to neutrophil and platelet
engraftment was calculated using the Kaplan-Meier
method; comparison was made with log-rank test. Over-
all survival (OS) and progression-free survival (PFS)
were estimated from date of transplantation using the
Kaplan-Meier method; death or relapse was considered
an event in the estimation of PFS. Accounting for com-
peting risk events, the cumulative incidence (CI) of
relapse and non-relapse mortality (NRM) was calculated
by the Gray method [20]. For OS and PFS, baseline vari-
ables were examined with univariable, and Cox propor-
tional hazard modeling. For CI of relapse and NRM, a
sub-distribution hazards regression model was utilized
for univariable and multivariable analysis [21]. For each
outcome, distinct models were created to examine pre-
and separately post-HCT variables. Pre-HCT variables
considered included the following: conditioning regimen,
cytogenetic risk group, donor relation, remission status,
number of induction cycles for CR1 patients, stem cell
source, GVHD prophylaxis regimen, primary vs. second-
ary AML, % blasts in bone marrow immediately prior to
HCT, white blood cell count at diagnosis of AML, age
at time of HCT, and time in CR1 for those who were
transplanted in CR2/3 or with relapsed disease. Post-
HCT variables considered included the following: maxi-
mum grade aGVHD, maximum grade cGVHD, donor
chimerism in bone marrow at day 90 post-HCT, and
donor CD3 and CD33 chimerism in peripheral blood on
day 90 post-HCT. Those variables with p value of 0.25
or less in univariable analysis were selected for construc-
tion of the multivariable model. The backward selection
procedure with a p-out value of 0.1 was utilized.
Results
One hundred consecutive adults with AML received
t-IV Bu/Flu, and 51 consecutive AML patients received
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Page 2 of 9Table 1 Baseline and transplant characteristics of patients in Bu/Cy and t-IV Bu/Flu groups
Variables Bu/Cy
(Freq/Percent)
Bu/Flu
(Freq/Percent)
Total
(Freq)
P-value
Name Level
Time from diagnosis to HCT Months (median value, range) 6.2 (1-29) 6.4 (2-54) 0.5
Follow up time Months (median value, range) 8 (1-90) 17 (1-53) 0.245
Donor MRD 51
100.00
39
39.00
81 <.0001
MUD 0
0.00
39
39.00
39
MMUD 0
0.00
22
22.00
22
Cytogenetic Low 3
7.89
7
7.00
10 0.3568
Intermediate 25
65.79
54
54.00
79
High 10
26.32
39
39.00
49
ATG No 42
100.00
78
78.79
120 0.0006
Yes 0
0.00
20
20.20
20
Cell Source BM 35
68.63
2
2.00
37 <.0001
PB 16
31.37
98
98.00
114
aGVHD prophylaxis CSA/MTX 51
100.00
0
0.00
42 <.0001
TAC/MMF 0
0.00
22
22.00
22
TAC/MTX 0
0.00
77
71.00
77
TAC/RAPA 0
0.00
1
1.00
1
Disease Status CR1 19
37.25
49
49.00
68 0.0013
CR2 or CR3 6
11.76
25
25.00
31
PIF 7
13.73
16
16.00
23
Relapse 18
35.29
9
9.00
27
UNT 1
1.96
1
1.00
2
Diagnosis primary 41
80.39
62
62.00
103 0.0221
secondary 10
19.61
38
38.00
48
No of Induction 0 1
2.38
1
1.00
2 0.4882
1 31
73.81
67
67.00
98
2 9
21.43
24
24.00
33
3 1
2.38
8
8.00
9
AGE 39.0 (19.6-55.60) 48.16(21.84-68.64) 0.0001
WBC at Diagnosis 13.60 (0.80-190.00) 5.80 (0.25-285.00) 0.1073
Time in CR1 256 (12-762) 324.5 (21 - 2679) 0.1699
% Blast in BM 4 (0 - 88) 2 (0-80) 0.0028
Chimerism (day 90) BM 100 (55-100) 97 (10-100) 0.0925
CD3 NA 90 (18-100) NA
CD33 NA 100 (10-100) NA
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mide (Bu/Cy). The t-IV Bu/Flu conditioning regimen
incorporated fludarabine, 40 mg/m
2 infused over 30
minutes on days -6 to -3, then intravenous busulfan,
130-145 mg/m2 over 4 hours daily on the same days.
Busulfan (Bu) PK-samples were obtained on day -6 and
analyzed by mass spectrometry; the BU dose was
adjusted on days -4 and -3 to achieve an overall average
AUC of 5300 (+/-10%) μMol*min (n = 96) or 3500
(+/-10%) μMol*min (n = 4) for each of the four days.
The median actual AUC after the first dose was 5113
μM*min (range 2796 - 9355) for the 5300 μM*min tar-
get subgroup and 4244 uM*min (range 2830 - 5347) for
the 3500 μM*min target subgroup. Daily busulfan doses
were adjusted to achieve the target AUC averaged over
4 days. Median total BU dose required to achieve the
target AUC was 520 mg/m
2 (range 370 - 974) in the
5300 μM/L*min group and 418 mg/m
2 (range 254 -
470) in the 3500 μM/L*min group. Baseline characteris-
tics are summarized in table 1. Importantly, there were
significant differences across the following baseline char-
acteristics in the Bu/Cy and t-IV Bu/Flu groups: donor
relation, stem cell source, aGVHD prophylaxis, remis-
sion status, primary vs. secondary disease, median age,
and % blasts prior to HCT.
Comparison of Bu/Cy vs. t-IV Bu/Flu: composite groups
Median time to neutrophil engraftment was 18 vs. 16
days (p < 0.001), and median time to platelet engraft-
ment was 21 vs. 12 days (p = 0.0002) for Bu/Cy and
t-IV Bu/Flu, respectively. Differences in engraftment are
attributable to the preponderance of peripheral blood
stem cells (PBSC) in the t-IV Bu/Flu group. There was a
greater burden of conditioning regimen related toxicity
observed after Bu/CY: There were 5 fatal cases of IPS
and 6 cases (mild 1; moderate 4; and severe, fatal case
1) of VOD after conditioning with Bu/Cy. Conversely, in
t h et - I VB u / F l ug r o u pt h e r ew a so n ec a s eo fi d i o p a t h i c
pneumonia syndrome (IPS) and no cases of hepatic
sinusoidal obstructive syndrome (VOD). While the ulti-
mate CI of non-relapse mortality (NRM) did not signifi-
cantly differ between groups (figure 1), early NRM was
reduced in the t-IV Bu/Flu group (table 2).
There were significant differences in grade II-IV aGVHD
(48% vs. 82%, p < 0.0001), as well as moderate/severe
cGVHD (7% vs. 40%, p < 0.0001) between the Bu/Cy and
t-IV Bu/Flu groups, respectively; the marked increase in
the incidence of GVHD observed in the t-IV Bu/Flu arm
is attributable to the greater proportion of PBSC. The dis-
parity in NRM in the first year after HCT suggests less
conditioning regimen toxicity after t-IV Bu/Flu. However,
NRM trends toward convergence over 1 and 2 years, likely
secondary to this increased risk of GVHD.
With median follow up for living patients of 54 months
(range 11 - 90) for Bu/CY and 28 months (range CI 2 -
54) for t-IV Bu/Flu, median OS was 8 months (95% CI
5.4 - 22) vs. 21 months (95% CI 10.9 - not reached),
respectively for each group (figure 2). Causes of death for
Bu/Cy were: infection (n = 4), relapse (n = 22), idiopathic
pneumonia syndrome (n = 5), hepatic VOD (n = 1),
multi-system organ failure (n = 1), unknown (n = 1), and
TTP/HUS (n = 1). Causes of death in the t-IV Bu/Flu
group included: refractory aGVHD (n = 4), refractory
cGVHD (n = 1), infection (n = 7), relapse (n = 29), multi-
organ system failure (n = 7), post-transplant lymphopro-
liferative disorder (n = 1), and unknown (n = 3). Median
PFS was 6.9 months (95% CI 4.1 - 20) in the Bu/Cy
group vs. 15.1 months (95% CI 9.1 - 30) in the t-IV Bu/
Flu group. There was no significant difference in the
cumulative incidence of AML relapse at day 100 (16% vs.
17%), 1 year (33% vs. 32%), or 2 years (40% vs. 37%) after
HCT in the comparison of Bu/Cy vs. t-IV Bu/Flu, respec-
tively, p = 0.68.
Comparison Bu/Cy vs. t-IV Bu/Flu according to disease
risk subgroups
Complete remission 1 (CR1)
Nineteen patients received Bu/Cy in CR1, and 49
received t-IV Bu/Flu in CR1. The proportion with pri-
mary vs. secondary AML in CR1 (Bu/Cy: primary n = 13,
secondary n = 6; t-IV Bu/Flu: primary n = 30, secondary
n = 19, Fisher exact p = 0.78) and cytogenetic risk group
(Bu/Cy: low n = 0, intermediate n = 10, high n = 3, n/a n
= 6; t-IV Bu/Flu: low n = 2, intermediate n = 26, high n =
21, Fisher exact p = 0.28) did not significantly differ
between the Bu/Cy and t-IV Bu/Flu groups. There was
no significant difference in OS between these groups (1
year OS 63% vs. 63%, and 2 year OS 63% and 58% for
Bu/Cy vs. t-IV Bu/Flu, p = 0.78) respectively (figure 3).
There was also no significant difference between groups
for those with primary AML in CR1 (1 year OS 69% vs.
66%, 2 year OS 69% vs. 62% for Bu/Cy vs. t-IV Bu/Flu, p
= 0.8) and those with secondary AML in CR1 (1 year OS
69% vs. 66%, 2 year OS 69% vs. 62% for Bu/Cy vs. t-IV
Bu/Flu, p = 0.9). As well, there was a non-significant
increase in early non-relapse mortality in the Bu/Cy
group (100 day 21% vs. 4%, 1 year 26% vs. 16%, and 2
year 26% vs. 21%, p = 0.98).
Complete remission 2 or 3 (CR2/3)
Six patients received Bu/Cy conditioning in CR 2/3 and
25 patients received t-IV Bu/Flu conditioning in CR 2/3.
O Sw a ss i g n i f i c a n t l yw o r s ei nt h o s ei nt h eB u / C yg r o u p
(1 year OS 17% vs. 59%, 2 year OS 17% vs. 41% for Bu/
Cy vs. t-IV Bu/Flu, p = 0.03). NRM (100 day 0% vs. 0%,
1 year 50% vs. 16%, and 2 years 50% vs. 24% for Bu/Cy
vs. t-IV Bu/Flu, p = 0.14) did not significantly differ.
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Seven patients received Bu/CY as conditioning in the set-
ting of primary induction failure, and 16 patients received
t-IV Bu/Flu. OS significantly differed (1 year OS 29% vs.
69%, 2 year OS 14% vs. 61% for Bu/Cy vs. t-IV Bu/Flu,
p = 0.01) between groups. NRM (100 day 0% vs. 0%, 1
year 14% vs. 6%, and 2 year 14% vs. 6% for Bu/Cy vs. t-IV
Bu/Flu, p = 0.58) did not significantly differ.
Refractory relapsed disease
Eighteen patients with refractory relapsed AML were
treated with Bu/Cy, and 9 received t-IV Bu/Flu. There
was no significant difference in OS (1 year OS 33% vs.
22%, 2 year OS 17% vs. 0% for Bu/Cy vs. t-IV Bu/Flu, p =
0.52). NRM (100 day 22% vs. 11%, 1 year 22% vs. 22%,
and 2 year 22% vs. n/a for Bu/Cy vs. t-IV Bu/Flu,
p = 0.61) did not significantly differ between groups.
Multivariable modeling
Baseline pre-transplant variables were first considered in
univariable analysis to evaluate the relationship of each
with OS. In the multivariable model, only relapsed
disease at time of HCT remained a significant predictor
of OS, HR 3.3 (95% CI 1.4 - 7.9; p = 0.007). Condition-
ing regimen did not significantly predict OS. In multi-
variable analysis of post-HCT variables, moderate/severe
cGVHD - HR of 0.4 (95% CI 0.18 - 0.88; p = 0.02) - and
day 90 bone marrow chimerism ≥ 90% - HR of 0.28
(95% CI 0.11 - 0.71; p = 0.008) - predicted OS.
Baseline variables were also examined in univariable
analysis to discern their relationship with progression-
free survival. On construction of a multivariable model
using pre-HCT variables, remission status emerged as
an independent predictor of PFS. In reference to CR1,
refractory relapsed disease predicted significantly worse
PFS, with HR 3.0 (95% CI 1.3 - 7; p = 0.01). Condition-
ing regimen did not significantly predict PFS. Examina-
tion of post-HCT variables in multivariable modeling
identified day 90 BM chimerism ≥ 90% as a significant
predictor: HR 0.18 (95% CI 0.08 - 0.42; p < 0.0001).
In multivariable analysis of pre-HCT variables, relapse
was significantly predicted by remission status: PIF (HR 3.0,
95% CI 1.2 - 7.5, p = 0.015) and refractory relapsed disease
(HR 3.8, 95% CI 1.4 - 10.3, p = 0.009) were associated with
significantly greater risk of relapse compared to a reference
of CR1. Conditioning regimen did not significantly predict
relapse. Of post-HCT variables, multivariable modeling
identified day 90 BM chimerism ≥ 90% as a protective
factor (HR 0.16, 95% CI 0.08 - 0.35, p < 0.001).
Finally, of pre-HCT variables, peripheral blood stem
cells were associated with less NRM (HR 0.34, 95%
Figure 1 Cumulative incidence of NRM according to conditioning regimen (p = 0.65).
Table 2 Non-relapse mortality according to treatment
regimen
t-IV Bu/Flu Bu/Cy
100 days 3% 16%
6 months 7% 18%
1 year 15% 25%
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of bone marrow stem cells in multivariable analysis.
Additionally, with reference of TAC/MMF aGVHD
prophylaxis, both CSA/MTX (HR 0.18, 95% CI 0.05 -
0.63, p = 0.01) and TAC/MTX (HR 0.41, 95% CI 0.18 -
0.93, p = 0.03) predicted significantly lower NRM on
multivariable modeling. There was a trend toward
decreased NRM in the t-IV Bu/Flu group (HR 0.83,
95% CI 0.41 - 1.7, p = 0.6) compared to Bu/Cy in
univariable analysis, which did not remain a signifi-
cant predictor of NRM on multivariable modeling. Of
post-HCT variables examined in uni- and multi-vari-
able analysis, grade III/IV aGVHD demonstrated a
non-significant trend toward greater NRM (HR 2.7,
95% CI 0.99 - 7.2, p = 0.053), as compared to a refer-
ence of grade 0/I.
Figure 2 Overall survival for total sample in Bu/Cy and t-IV Bu/Flu groups (log-rank p = 0.0356).
Figure 3 Overall survival for those in CR1 at time of HCT, stratified by conditioning regimen (log-rank p = 0.78).
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Recognizing the adverse outcomes potentiated by varia-
tion in bioavailability of oral busulfan, as well as
increased toxicity from aberrant metabolism of cyclo-
phosphamide, there was a shift in the institutional prac-
tice at our center, wherein those consecutive AML
patients transplanted from 2004 onward received intra-
venous PK-targeted busulfan combined with fludarabine
(t-IV Bu/Flu) as conditioning therapy. We aimed to
compare these outcomes to a historical cohort of AML
patients, who received Bu/Cy as conditioning therapy in
a single institution.
The most consistent finding from this analysis is the
reduction in conditioning regimen related toxicity as
well as reduction in early transplant related mortality
with the adoption of t-IV Bu/Flu. A near elimination of
severe busulfan toxicity including idiopathic pneumonia
syndrome and hepatic veno-occlusive disease represents
a major advantage in early HCT outcomes favoring t-IV
Bu/Flu. These data corroborate the reduction in condi-
tioning regimen toxicity anticipated with both pharma-
cokinetic targeting of busulfan, and avoidance of
cyclophosphamide and it metabolites [3]. As well, while
the ultimate cumulative incidence of NRM did not sig-
nificantly differ between the t-IV Bu/Flu and Bu/Cy
groups, the trajectory of NRM differed with less NRM
at day 100 and 1 year in the t-IV Bu/Flu group. The sig-
nificantly greater burden of aGVHD and severe cGVHD
in the t-IV Bu/Flu group, explained by the predomi-
nance of peripheral blood stem cells, burden of unre-
lated and mismatched unrelated donors, and older age,
resulted in the later approximation of these NRM
curves. We acknowledge that these data on trends in
early NRM and GVHD related outcomes are likely
dependent upon the predominance of peripheral blood
stem cells in the t-IV Bu/Flu group.
Of the 100 AML patients treated with t-IV Bu/Flu and
51 treated with Bu/Cy, there were important differences in
baseline variables which circumscribe other comparisons.
First, transplant conditions differed, which complicates
observed differences in non-relapse mortality between
groups: While the Bu/Cy group only included matched
sibling donors, the t-IV Bu/Flu group included matched
sibling donors, but the majority (61%) were either unre-
lated or mismatched unrelated donors. This in particular,
as well as the significantly increased age and predomi-
nance of peripheral blood stem cells (98% of subjects) in
the t-IV Bu/Flu group likely account for the significantly
increased grade II-IV aGVHD and moderate/severe
cGVHD realized in the t-IV Bu/Flu group. Second, the
Bu/Cy and t-IV Bu/Flu groups differ according to disease
risk variables, with a greater proportion of refractory
relapsed disease at HCT in the Bu/Cy group, and conver-
sely a greater proportion with secondary AML in the t-IV
Bu/Flu group. The net effect of these disparate transplant
and disease risk variables is difficult to discern. Accord-
ingly, we have reported outcomes according to remission
status, and also examined these variables in uni- and
multi-variable modeling to discern the impact of condi-
tioning regimen on outcome.
Acknowledging differences in disease risk variables
between groups as well as the predominant use of PBSC
in the t-IV Bu/Flu group, these results do not demon-
strate significant differences in disease control between
the two approaches. The cumulative incidence of relapse
observed across groups both in the overall sample, as
well as for each remission status subgroup, was similar.
As well, conditioning regimen was not significantly asso-
ciated with relapse on multivariable modeling. Specific
conclusions regarding the impact of conditioning regi-
men on disease control among specific remission status
groups are limited by small sample sizes. The most
important predictor of relapse post-HCT in this series of
AML patients was remission status at the time of HCT.
In total, these results demonstrate a reduction in
conditioning regimen related toxicity and mortality
after t-IV Bu/Flu for HCT in a consecutive series of
adult AML patients. Previously published retrospective
comparisons between comparable regimens of IV Bu/
Flu and Bu/Cy have also demonstrated reduced toxicity
in keeping with the conclusions of our analysis. In a
retrospective analysis, Andersson, et al compared IV
Bu/Flu and IV Bu/Cy2 as conditioning therapy for
AML and MDS; groups differed significantly, with
older age and a greater proportion of unrelated donors
in the IV Bu/Flu group. Overall survival was signifi-
cantly better in the IV Bu/Flu group [22]. Bredeson,
et al compared IV Flu/Bu/ATG to oral Bu/Cy in a
matched pair analysis compared to registry data
including a heterogeneous array of hematologic malig-
nancies; the Flu/Bu/ATG group had significantly older
age, worse performance status, greater proportion of
PBSC, and was transplanted in a later time period.
This analysis demonstrated significantly decreased
NRM in the Flu/Bu/ATG group [23]. Finally, Chae, et
al compared IV Bu/Flu and oral Bu/Cy2; patient age
was significantly greater in the IV Bu/Flu group. NRM
was lower, and overall survival was significantly greater
in the IV Bu/Flu group [24]. Overall, these retrospec-
tive comparisons suggest a significant advantage in
transplantation outcomes favoring IV Bu/Flu. Rando-
mized clinical trial data is needed to determine the
true benefit of IV Bu/Flu over Bu/Cy conditioning for
allogeneic HCT in acute myelogenous leukemia.
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